BIVRX | CPCLX | BIVRX / CPCLX | |
Total Expense Ratio | 3.33 | 3.19 | 104% |
Annual Report Gross Expense Ratio | 3.33 | 3.19 | 104% |
Fund Existence | 8 years | 9 years | - |
Gain YTD | 2.771 | 1.588 | 174% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 5000 | 2500 | 200% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 1.15B | 1.02B | 113% |
Annual Yield % from dividends | 3.43 | 3.09 | 111% |
Returns for 1 year | -1.03 | 1.02 | -100% |
Returns for 3 years | -16.42 | 3.44 | -477% |
Returns for 5 years | 87.72 | 70.39 | 125% |
Returns for 10 years | N/A | N/A | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
LQDI | 26.03 | -0.05 | -0.20% |
iShares Inflation Hedged Corp Bd ETF | |||
CLOZ | 26.20 | -0.20 | -0.76% |
Eldridge BBB-B CLO ETF | |||
PJP | 82.63 | -1.82 | -2.16% |
Invesco Pharmaceuticals ETF | |||
CEFD | 18.32 | -0.59 | -3.12% |
ETRACS Monthly Pay 1.5X Lvgd CE Fd ETN | |||
SPYD | 42.54 | -1.74 | -3.93% |
SPDR® Portfolio S&P 500® High Div ETF |